{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"5.6","upperLimit":"10.9","value":"7.1"},{"groupId":"OG001","lowerLimit":"5.4","upperLimit":"8.1","value":"5.6"}]}],"title":"Assessed by Blinded Independent Central Review"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"6.7","upperLimit":"11.1","value":"9.6"},{"groupId":"OG001","lowerLimit":"5.1","upperLimit":"8.3","value":"6.4"}]}],"title":"Assessed by Investigator"}],"denoms":[{"counts":[{"groupId":"OG000","value":"299"},{"groupId":"OG001","value":"305"}],"units":"Participants"}],"description":"DOR is defined as the time from the date of the first documentation of objective response (confirmed CR or confirmed PR) to the date of the first documentation of radiographic Progressive Disease or death due to any cause, whichever occurs first.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants were randomized to receive 6.0 mg/kg of DS-1062a.","id":"OG000","title":"DS-1062a 6.0 mg/kg"},{"description":"Participants were randomized to receive 75 mg/m\\^2 docetaxel.","id":"OG001","title":"Docetaxel 75 mg/m^2"}],"paramType":"MEDIAN","populationDescription":"Full Analysis Set includes all randomized subjects. If a subject was randomized more than once, only one of the participants is included in the Full Analysis Set.","reportingStatus":"POSTED","timeFrame":"From date of first objective response (CR or PR) to date of first radiographic disease progression or death due to any cause (whichever occurs first), up to approximately 43 months","title":"Duration of Response (DOR) As Assessed by Blinded Independent Central Review (BICR) and Investigator As Per RECIST v1.1 Following DS-1062a Versus Docetaxel","type":"SECONDARY","unitOfMeasure":"months"}